[ad_1]
Noul Co., a Korean firm specializing in AI-based blood and most cancers diagnostics, introduced on Jan. 28 that it has signed a contract to provide its AI-based cervical most cancers diagnostic answer, miLab CER, to the Mexican market.
Via this contract, Noul will associate with a significant medical system distributor with a powerful gross sales community in Mexico to completely provide 100 items of miLab CER over 4 years. This settlement follows a 1.1 billion gained deal to provide miLab CER to Panama final yr. It’s anticipated to function a possibility to broaden the corporate’s market affect all through Latin America.
As Noul lately proved its international competitiveness by acquiring the MDSAP certification, which meets the built-in high quality requirements of main international locations in North and Latin America, the corporate plans to additional speed up its international enterprise enlargement, together with entry into the North American market in addition to enterprise enlargement within the Latin American market.
Noul CEO Lim Chan-yang acknowledged, “Mexico is a strategic hub for increasing into the Latin American market, and miLab CER will play a key function in driving Noul’s gross sales development and profitability all through Latin America sooner or later.” He added, “This yr, Noul will concentrate on maximizing gross sales and enhancing profitability by accelerating the enlargement of provide to main abroad markets similar to Latin America and Europe, centered on high-value-added new merchandise together with not solely our AI-based cervical most cancers answer but in addition blood evaluation options. Via this, we are going to safe steady development momentum for our international enterprise.”
[ad_2]
